- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.
Meet our expert team
Working at the cutting edge of epigenetics.

It’s all in our name: Volition means to have determination and a purpose.
We have a team of over 80 dedicated staff, spanning a wide range of disciplines.
We are dedicated to advancing the science of epigenetics and we are united in our mission to save lives and improve outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Cameron Reynolds MBA
President & Group Chief Executive Officer

Terig Hughes
Group Chief Financial Officer

Gaetan Michel PhD
Chief Operating Officer

Nick Plummer
Group General Counsel

Louise Batchelor
Group Chief Marketing & Communications Officer

Dr Andrew Retter BSC, MBBS, MRCP, FRCPATH(HAEM), DICM
Chief Medical Officer

Jake Micallef PhD. MBA
Chief Scientific Officer

Tom Butera DVM
Chief Executive Officer, Volition Veterinary Diagnostics Development LLC

Gael Forterre MBA
Chief Commercial Officer

Jasmine Kway PhD
Chief Executive Officer, Singapore Volition

Rod Rootsaert LLB
Corporate Secretary

Timothy I. Still
Chairman

Cameron Reynolds MBA
President & Group Chief Executive Officer

Guy Innes ACA
Independent Director

Mickie Henshall
Independent Director

Dr. Phillip Barnes BSc, PhD, BMBCh
Independent Director

Kim Nguyen
Independent Director

Dr Alan Colman
Independent Director & Member of Scientific Advisory Board

Dr. Ethel Rubin PhD
Independent Director